U.S. High Court Endorses Federal Circuit Enablement Standard
WASHINGTON, D.C. — A unanimous U.S. Supreme Court on May 18 affirmed trial court and circuit court rulings that two Amgen Inc. patents on anti-cholesterol antibodies are not sufficiently enabled because...To view the full article, register now.
Already a subscriber? Click here to view full article